vs
拜玛林制药（BMRN）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是拜玛林制药的1.2倍（$1.0B vs $874.6M），越洋钻探净利率更高（2.4% vs -5.3%，领先7.7%），拜玛林制药同比增速更快（17.0% vs 9.6%），越洋钻探自由现金流更多（$321.0M vs $58.9M），过去两年越洋钻探的营收复合增速更高（16.9% vs 16.1%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
BMRN vs RIG — 直观对比
营收规模更大
RIG
是对方的1.2倍
$874.6M
营收增速更快
BMRN
高出7.5%
9.6%
净利率更高
RIG
高出7.7%
-5.3%
自由现金流更多
RIG
多$262.1M
$58.9M
两年增速更快
RIG
近两年复合增速
16.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $1.0B |
| 净利润 | $-46.6M | $25.0M |
| 毛利率 | 68.5% | 42.0% |
| 营业利润率 | -5.1% | 23.0% |
| 净利率 | -5.3% | 2.4% |
| 营收同比 | 17.0% | 9.6% |
| 净利润同比 | -137.3% | 257.1% |
| 每股收益（稀释后） | $-0.22 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRIG
| Q4 25 | $874.6M | $1.0B | ||
| Q3 25 | $776.1M | $1.0B | ||
| Q2 25 | $825.4M | $988.0M | ||
| Q1 25 | $745.1M | $906.0M | ||
| Q4 24 | $747.3M | $952.0M | ||
| Q3 24 | $745.7M | $948.0M | ||
| Q2 24 | $712.0M | $861.0M | ||
| Q1 24 | $648.8M | $763.0M |
净利润BMRNRIG
| Q4 25 | $-46.6M | $25.0M | ||
| Q3 25 | $-30.7M | $-1.9B | ||
| Q2 25 | $240.5M | $-938.0M | ||
| Q1 25 | $185.7M | $-79.0M | ||
| Q4 24 | $124.9M | $7.0M | ||
| Q3 24 | $106.1M | $-494.0M | ||
| Q2 24 | $107.2M | $-123.0M | ||
| Q1 24 | $88.7M | $98.0M |
毛利率BMRNRIG
| Q4 25 | 68.5% | 42.0% | ||
| Q3 25 | 82.0% | 43.2% | ||
| Q2 25 | 81.8% | 39.4% | ||
| Q1 25 | 79.7% | 31.8% | ||
| Q4 24 | 81.8% | 39.2% | ||
| Q3 24 | 74.7% | 40.6% | ||
| Q2 24 | 81.7% | 38.0% | ||
| Q1 24 | 80.7% | 31.5% |
营业利润率BMRNRIG
| Q4 25 | -5.1% | 23.0% | ||
| Q3 25 | -6.0% | -163.1% | ||
| Q2 25 | 33.5% | -97.6% | ||
| Q1 25 | 30.0% | 7.1% | ||
| Q4 24 | 21.6% | 13.7% | ||
| Q3 24 | 15.3% | -51.2% | ||
| Q2 24 | 16.9% | -6.9% | ||
| Q1 24 | 13.6% | -0.4% |
净利率BMRNRIG
| Q4 25 | -5.3% | 2.4% | ||
| Q3 25 | -4.0% | -187.1% | ||
| Q2 25 | 29.1% | -94.9% | ||
| Q1 25 | 24.9% | -8.7% | ||
| Q4 24 | 16.7% | 0.7% | ||
| Q3 24 | 14.2% | -52.1% | ||
| Q2 24 | 15.1% | -14.3% | ||
| Q1 24 | 13.7% | 12.8% |
每股收益（稀释后）BMRNRIG
| Q4 25 | $-0.22 | $0.13 | ||
| Q3 25 | $-0.16 | $-2.00 | ||
| Q2 25 | $1.23 | $-1.06 | ||
| Q1 25 | $0.95 | $-0.11 | ||
| Q4 24 | $0.65 | $-0.14 | ||
| Q3 24 | $0.55 | $-0.58 | ||
| Q2 24 | $0.55 | $-0.15 | ||
| Q1 24 | $0.46 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $620.0M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $6.1B | $8.1B |
| 总资产 | $7.6B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资BMRNRIG
| Q4 25 | $1.3B | $620.0M | ||
| Q3 25 | $1.3B | $833.0M | ||
| Q2 25 | $1.2B | $377.0M | ||
| Q1 25 | $1.0B | $263.0M | ||
| Q4 24 | $942.8M | $560.0M | ||
| Q3 24 | $675.4M | $435.0M | ||
| Q2 24 | $972.1M | $475.0M | ||
| Q1 24 | $747.0M | $446.0M |
总债务BMRNRIG
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.9B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $6.2B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $6.8B |
股东权益BMRNRIG
| Q4 25 | $6.1B | $8.1B | ||
| Q3 25 | $6.1B | $8.1B | ||
| Q2 25 | $6.0B | $9.4B | ||
| Q1 25 | $5.8B | $10.2B | ||
| Q4 24 | $5.7B | $10.3B | ||
| Q3 24 | $5.4B | $10.2B | ||
| Q2 24 | $5.3B | $10.7B | ||
| Q1 24 | $5.1B | $10.5B |
总资产BMRNRIG
| Q4 25 | $7.6B | $15.6B | ||
| Q3 25 | $7.6B | $16.2B | ||
| Q2 25 | $7.5B | $17.8B | ||
| Q1 25 | $7.1B | $19.0B | ||
| Q4 24 | $7.0B | $19.4B | ||
| Q3 24 | $6.9B | $19.5B | ||
| Q2 24 | $7.1B | $20.3B | ||
| Q1 24 | $6.9B | $19.9B |
负债/权益比BMRNRIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $321.0M |
| 自由现金流率自由现金流/营收 | 6.7% | 30.8% |
| 资本支出强度资本支出/营收 | 4.7% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 13.96× |
| 过去12个月自由现金流最近4个季度 | $725.0M | $626.0M |
8季度趋势，按日历期对齐
经营现金流BMRNRIG
| Q4 25 | $99.6M | $349.0M | ||
| Q3 25 | $368.7M | $246.0M | ||
| Q2 25 | $185.3M | $128.0M | ||
| Q1 25 | $174.4M | $26.0M | ||
| Q4 24 | $185.6M | $206.0M | ||
| Q3 24 | $221.5M | $194.0M | ||
| Q2 24 | $118.8M | $133.0M | ||
| Q1 24 | $47.0M | $-86.0M |
自由现金流BMRNRIG
| Q4 25 | $58.9M | $321.0M | ||
| Q3 25 | $340.2M | $235.0M | ||
| Q2 25 | $168.2M | $104.0M | ||
| Q1 25 | $157.6M | $-34.0M | ||
| Q4 24 | $166.1M | $177.0M | ||
| Q3 24 | $203.0M | $136.0M | ||
| Q2 24 | $97.4M | $49.0M | ||
| Q1 24 | $20.9M | $-169.0M |
自由现金流率BMRNRIG
| Q4 25 | 6.7% | 30.8% | ||
| Q3 25 | 43.8% | 22.9% | ||
| Q2 25 | 20.4% | 10.5% | ||
| Q1 25 | 21.2% | -3.8% | ||
| Q4 24 | 22.2% | 18.6% | ||
| Q3 24 | 27.2% | 14.3% | ||
| Q2 24 | 13.7% | 5.7% | ||
| Q1 24 | 3.2% | -22.1% |
资本支出强度BMRNRIG
| Q4 25 | 4.7% | 2.7% | ||
| Q3 25 | 3.7% | 1.1% | ||
| Q2 25 | 2.1% | 2.4% | ||
| Q1 25 | 2.3% | 6.6% | ||
| Q4 24 | 2.6% | 3.0% | ||
| Q3 24 | 2.5% | 6.1% | ||
| Q2 24 | 3.0% | 9.8% | ||
| Q1 24 | 4.0% | 10.9% |
现金转化率BMRNRIG
| Q4 25 | — | 13.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.49× | 29.43× | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.53× | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
